Works in Investigational New Drugs, 2018, Vol 36, Issue 4

Results: 25

Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 702, doi. 10.1007/s10637-018-0603-z

By:

Nakayama, Hiroki;
Tsukamoto, Katsura

Publication type:

Article

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 674, doi. 10.1007/s10637-018-0599-4

By:

Lui, Arthur;
Mulder, Karen;
Brezden-Masley, Christine;
Vickers, Michael;
Monzon, Jose;
Kennecke, Hagen;
Goel, Rakesh;
Vos, Larissa;
Ghosh, Sunita;
Marginean, Horia;
Fields, Anthony;
Maroun, Jean;
Spratlin, Jennifer

Publication type:

Article

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 732, doi. 10.1007/s10637-018-0598-5

By:

Kang, Jihoon;
Hwang, Inhwan;
Yoo, Changhoon;
Kim, Kyu-pyo;
Jeong, Jae Ho;
Chang, Heung-Moon;
Lee, Sang Soo;
Park, Do Hyun;
Song, Tae Jun;
Seo, Dong Wan;
Lee, Sung Koo;
Kim, Myung-Hwan;
Hong, Seung-Mo;
Shin, Sang Hyun;
Hwang, Dae Wook;
Song, Ki Byung;
Lee, Jae Hoon;
Kim, Song Cheol;
Ryoo, Baek-Yeol

Publication type:

Article

Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 726, doi. 10.1007/s10637-018-0596-7

By:

Nakatani, Yoshihisa;
Kawakami, Hisato;
Ichikawa, Masashi;
Yamamoto, Sachiyo;
Otsuka, Yasuo;
Mashiko, Akiko;
Takashima, Yasutoshi;
Ito, Akihiko;
Nakagawa, Kazuhiko;
Arima, Shuji

Publication type:

Article

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 683, doi. 10.1007/s10637-018-0580-2

By:

Hurwitz, Herbert;
Van Cutsem, Eric;
Bendell, Johanna;
Hidalgo, Manuel;
Li, Chung-Pin;
Salvo, Marcelo Garrido;
Macarulla, Teresa;
Sahai, Vaibhav;
Sama, Ashwin;
Greeno, Edward;
Yu, Kenneth H.;
Verslype, Chris;
Dawkins, Fitzroy;
Walker, Chris;
Clark, Jason;
O’Reilly, Eileen M.

Publication type:

Article

Autophagy inhibition improves the chemotherapeutic efficacy of cruciferous vegetable-derived diindolymethane in a murine prostate cancer xenograft model.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 718, doi. 10.1007/s10637-018-0595-8

By:

Draz, Hossam;
Goldberg, Alexander A.;
Tomlinson Guns, Emma S.;
Fazli, Ladan;
Safe, Stephen;
Sanderson, J. Thomas

Publication type:

Article

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 715, doi. 10.1007/s10637-018-0586-9

By:

Tanaka, Midori;
Ishii, Hidenobu;
Moribuchi, Hayato;
Naito, Yoshiko;
Matsuo, Norikazu;
Nakamura, Masayuki;
Tokito, Takaaki;
Azuma, Koichi;
Yamada, Kazuhiko;
Hoshino, Tomoaki

Publication type:

Article

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 657, doi. 10.1007/s10637-018-0585-x

By:

Kasner, Margaret T.;
Mick, Rosemarie;
Jeschke, Grace R.;
Carabasi, Matthew;
Filicko-O’Hara, Joanne;
Flomenberg, Neal;
Frey, Noelle V.;
Hexner, Elizabeth O.;
Luger, Selina M.;
Loren, Alison W.;
Mangan, James K.;
Wagner, John L.;
Weiss, Mark;
Carroll, Martin;
Perl, Alexander E.

Publication type:

Article

Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 696, doi. 10.1007/s10637-018-0581-1

By:

Tamiya, Motohiro;
Suzuki, Hidekazu;
Shiroyama, Takayuki;
Tanaka, Ayako;
Morishita, Naoko;
Okamoto, Norio;
Sakai, Kenichi;
Shigeoka, Hironori;
Kawahara, Kunimitsu;
Hirashima, Tomonori

Publication type:

Article

Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 709, doi. 10.1007/s10637-018-0579-8

By:

Di Desidero, Teresa;
Orlandi, Paola;
Fioravanti, Anna;
Cremolini, Chiara;
Loupakis, Fotios;
Marmorino, Federica;
Antoniotti, Carlotta;
Masi, Gianluca;
Lonardi, Sara;
Bergamo, Francesca;
Zagonel, Vittorina;
Falcone, Alfredo;
Bocci, Guido

Publication type:

Article

A phase I/II trial of pemetrexed plus radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 667, doi. 10.1007/s10637-018-0587-8

By:

Tamiya, Akihiro;
Morimoto, Masahiro;
Fukuda, Shoichi;
Naoki, Yoko;
Ibe, Tatsuya;
Okishio, Kyoichi;
Goto, Hideto;
Yoshii, Akihiro;
Kita, Toshiyuki;
Nogami, Naoyuki;
Fujita, Yuka;
Atagi, Shinji

Publication type:

Article

Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 590, doi. 10.1007/s10637-017-0557-6

By:

Liu, Hsiu-Yu;
Tuckett, Andrea Z.;
Fennell, Myles;
Garippa, Ralph;
Zakrzewski, Johannes L.

Publication type:

Article

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 581, doi. 10.1007/s10637-017-0556-7

By:

Canonici, Alexandra;
Qadir, Zulfiqar;
Conlon, Neil T.;
Collins, Denis M.;
O’Brien, Neil A.;
Walsh, Naomi;
Eustace, Alex J.;
O’Donovan, Norma;
Crown, John

Publication type:

Article

Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 571, doi. 10.1007/s10637-017-0552-y

By:

Zhou, Jianan;
Zhang, Canjing;
Sui, Xianxian;
Cao, Shengxuan;
Tang, Feng;
Sun, Shuhui;
Wang, Songmei;
Chen, Bobin

Publication type:

Article

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 561, doi. 10.1007/s10637-017-0550-0

By:

Benbrook, Doris M.;
Janakiram, Naveena B.;
Chandra, Vishal;
Pathuri, Gopal;
Madka, Venkateshwar;
Stratton, Nicole C.;
Masamha, Chioniso P.;
Farnsworth, Cassadie N.;
Garcia-Contreras, Lucila;
Hatipoglu, Manolya Kukut;
Lighfoot, Stan;
Rao, Chinthalapally V.

Publication type:

Article

Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 545, doi. 10.1007/s10637-017-0547-8

By:

Lee, Hak-Min;
Lee, Eunmyong;
Yeo, So-Young;
Shin, Sang;
Park, Hyun-Kyu;
Nam, Do-Hyun;
Kim, Seok-Hyung

Publication type:

Article

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 536, doi. 10.1007/s10637-017-0545-x

By:

Yan, S. Betty;
Um, Suzane L.;
Peek, Victoria L.;
Stephens, Jennifer R.;
Zeng, Wei;
Konicek, Bruce W.;
Liu, Ling;
Manro, Jason R.;
Wacheck, Volker;
Walgren, Richard A.

Publication type:

Article

A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 647, doi. 10.1007/s10637-017-0544-y

By:

Ueno, Hideki;
Kondo, Shunsuke;
Yoshikawa, Shusuke;
Inoue, Koichi;
Andre, Valérie;
Tajimi, Masaomi;
Murakami, Haruyasu

Publication type:

Article

Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 523, doi. 10.1007/s10637-017-0543-z

By:

Pollock, Jade K.;
Greene, Lisa M.;
Nathwani, Seema M.;
Kinsella, Paula;
O’Boyle, Niamh M.;
Meegan, Mary J.;
Zisterer, Daniela M.

Publication type:

Article

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 638, doi. 10.1007/s10637-017-0534-0

By:

Fujii, Takeo;
Colen, Rivka R.;
Bilen, Mehmet Asim;
Hess, Kenneth R.;
Hajjar, Joud;
Suarez-Almazor, Maria E.;
Alshawa, Anas;
Hong, David S.;
Tsimberidou, Apostolia;
Janku, Filip;
Gong, Jing;
Stephen, Bettzy;
Subbiah, Vivek;
Piha-Paul, Sarina A.;
Fu, Siqing;
Sharma, Padmanee;
Mendoza, Tito;
Patel, Anisha;
Thirumurthi, Selvi;
Sheshadri, Ajay

Publication type:

Article

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 629, doi. 10.1007/s10637-017-0532-2

By:

Goldman, Jonathan W.;
Rosen, Lee S.;
Tolcher, Anthony W.;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Shi, Peipei;
Pitou, Celine;
Bell, Robert;
Kulanthaivel, Palaniappan;
Zhang, Xuekui;
Fink, Aaron;
Chan, Edward M.;
Shahir, Ashwin;
Farrington, Daphne;
Patnaik, Amita

Publication type:

Article

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 619, doi. 10.1007/s10637-017-0531-3

By:

Bahleda, Rastislav;
Le Deley, Marie-Cécile;
Bernard, Apexa;
Chaturvedi, Shalini;
Hanley, Michael;
Poterie, Audrey;
Gazzah, Anas;
Varga, Andreea;
Touat, Mehdi;
Deutsch, Eric;
Massard, Christophe;
Van De Velde, Helgi;
Hollebecque, Antoine;
Sallansonnet-Froment, Magali;
Ricard, Damien;
Taillia, Hervé;
Angevin, Eric;
Ribrag, Vincent;
Soria, Jean-Charles

Publication type:

Article

Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 615, doi. 10.1007/s10637-017-0528-y

By:

Pappot, H.;
von der Maase, H.;
Ullén, A.;
Agerbæk, M.;
on behalf of NUCOG - Nordic Urothelial Cancer Oncology Group (NUCOG)

Publication type:

Article

Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 601, doi. 10.1007/s10637-017-0524-2

By:

Colen, Rivka R.;
Fujii, Takeo;
Bilen, Mehmet Asim;
Kotrotsou, Aikaterini;
Abrol, Srishti;
Hess, Kenneth R.;
Hajjar, Joud;
Suarez-Almazor, Maria E.;
Alshawa, Anas;
Hong, David S.;
Giniebra-Camejo, Dunia;
Stephen, Bettzy;
Subbiah, Vivek;
Sheshadri, Ajay;
Mendoza, Tito;
Fu, Siqing;
Sharma, Padmanee;
Meric-Bernstam, Funda;
Naing, Aung

Publication type:

Article

Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.

Published in:

Investigational New Drugs, 2018, v. 36, n. 4, p. 608, doi. 10.1007/s10637-017-0527-z

By:

Tamiya, Motohiro;
Tamiya, Akihiro;
Shiroyama, Takayuki;
Takeoka, Sawa;
Naito, Yujiro;
Omachi, Naoki;
Kimura, Yohei;
Morishita, Naoko;
Suzuki, Hidekazu;
Okamoto, Norio;
Okishio, Kyoichi;
Kawaguchi, Tomoya;
Atagi, Shinji;
Hirashima, Tomonori

Publication type:

Article